XyloCor Therapeutics, Inc., ("XyloCor"), a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of a $67.5 million Series ...
12hon MSN
XyloCor Therapeutics Inc., a Wayne gene therapy company, received $67.5 million from investors to support Phase 2 trials of a treatment designed to grow new blood vessels in the heart, XyloCor ...
A new type of bioengineered blood vessel has shown strong results in treating severe vascular injuries, potentially offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback